BRPI1006231A2 - ''complexo composto por ma insulina e um polissacarídeo contendo grupos carboxila funcionais, composição farmacêutica e uso do complexo'' - Google Patents
''complexo composto por ma insulina e um polissacarídeo contendo grupos carboxila funcionais, composição farmacêutica e uso do complexo''Info
- Publication number
- BRPI1006231A2 BRPI1006231A2 BRPI1006231-9A BRPI1006231A BRPI1006231A2 BR PI1006231 A2 BRPI1006231 A2 BR PI1006231A2 BR PI1006231 A BRPI1006231 A BR PI1006231A BR PI1006231 A2 BRPI1006231 A2 BR PI1006231A2
- Authority
- BR
- Brazil
- Prior art keywords
- complex
- insulin
- pharmaceutical composition
- carboxyl groups
- functional carboxyl
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 10
- 102000004877 Insulin Human genes 0.000 title abstract 5
- 108090001061 Insulin Proteins 0.000 title abstract 5
- 150000004676 glycans Chemical class 0.000 title abstract 5
- 229940125396 insulin Drugs 0.000 title abstract 5
- 229920001282 polysaccharide Polymers 0.000 title abstract 5
- 239000005017 polysaccharide Substances 0.000 title abstract 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 150000002993 phenylalanine derivatives Chemical class 0.000 abstract 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract 1
- OBSIQMZKFXFYLV-QMMMGPOBSA-N L-phenylalanine amide Chemical compound NC(=O)[C@@H](N)CC1=CC=CC=C1 OBSIQMZKFXFYLV-QMMMGPOBSA-N 0.000 abstract 1
- STVVMTBJNDTZBF-VIFPVBQESA-N L-phenylalaninol Chemical compound OC[C@@H](N)CC1=CC=CC=C1 STVVMTBJNDTZBF-VIFPVBQESA-N 0.000 abstract 1
- 229910052783 alkali metal Inorganic materials 0.000 abstract 1
- -1 alkali metal cation salts Chemical class 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 abstract 1
- 229950004152 insulin human Drugs 0.000 abstract 1
- HVAAHUDGWQAAOJ-UHFFFAOYSA-N n-benzylethanamine Chemical compound CCNCC1=CC=CC=C1 HVAAHUDGWQAAOJ-UHFFFAOYSA-N 0.000 abstract 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
complexo composto por uma insulina e um polissacarídeo contendo grupos carboxila funcionais, composição farmacêutica e uso do complexo a invenção refere-se a um complexo entre uma insulina e um polissacarídeo compreendendo grupos carboxila funcionais, dito polissacarídeo sendo escolhido a partir de polissacarídeos funcionalizados com pelo menos um derivado de fenilalanina, denominado fe, dito derivado de fenilalanina sendo escolhido a partir do grupo composto por fenilalanina e seus sais de cátions de metais alcalinos, fenilalaninol, fenilalaninamida e etilbenzilamina ou a partir de ésteres de fenilalanina, e dita insulina sendo tanto uma insulina humana ou uma insulina análoga. a invenção também se refere a uma composição farmacêutica compreendendo pelo menos um complexo de acordo com a invenção, especialmente na forma de uma solução injetável.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20269209P | 2009-03-27 | 2009-03-27 | |
| FR09/01478 | 2009-03-27 | ||
| US61/202,692 | 2009-03-27 | ||
| FR0901478A FR2943538B1 (fr) | 2009-03-27 | 2009-03-27 | Formulation a action rapide d'insuline recombinante humaine |
| PCT/IB2010/000711 WO2010122385A1 (fr) | 2009-03-27 | 2010-03-29 | Formulation a action rapide d'insuline |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1006231A2 true BRPI1006231A2 (pt) | 2019-03-26 |
Family
ID=41139484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1006231-9A BRPI1006231A2 (pt) | 2009-03-27 | 2010-03-26 | ''complexo composto por ma insulina e um polissacarídeo contendo grupos carboxila funcionais, composição farmacêutica e uso do complexo'' |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8669227B2 (pt) |
| EP (1) | EP2411037B1 (pt) |
| JP (1) | JP2012521980A (pt) |
| KR (1) | KR20110137815A (pt) |
| CN (1) | CN102369019A (pt) |
| AU (1) | AU2010240664A1 (pt) |
| BR (1) | BRPI1006231A2 (pt) |
| CA (1) | CA2756074A1 (pt) |
| FR (1) | FR2943538B1 (pt) |
| IL (1) | IL215122A0 (pt) |
| MX (1) | MX2011010071A (pt) |
| RU (1) | RU2500420C2 (pt) |
| SG (1) | SG174912A1 (pt) |
| WO (1) | WO2010122385A1 (pt) |
| ZA (1) | ZA201106755B (pt) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2943538B1 (fr) | 2009-03-27 | 2011-05-20 | Adocia | Formulation a action rapide d'insuline recombinante humaine |
| US9018190B2 (en) | 2009-03-27 | 2015-04-28 | Adocia | Functionalized oligosaccharides |
| FR2984749A1 (fr) * | 2011-12-23 | 2013-06-28 | Adocia | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 en combinaison avec une hormone gastro-intestinale a visee therapeutique |
| DK2741765T3 (en) * | 2011-08-10 | 2016-06-13 | Adocia | Injectable solution of at least one type of basal insulin |
| FR2978918B1 (fr) * | 2011-08-10 | 2013-12-27 | Adocia | Solution injectable a ph7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 |
| EP2773675B1 (fr) * | 2011-11-02 | 2023-03-01 | Adocia | Formulation à action rapide d'insuline comprenant un oligosaccharide |
| US20130231281A1 (en) | 2011-11-02 | 2013-09-05 | Adocia | Rapid acting insulin formulation comprising an oligosaccharide |
| US9198971B2 (en) | 2012-01-09 | 2015-12-01 | Adocia | Injectable solution at pH 7 comprising at least one basal insulin the pI of which is between 5.8 and 8.5 and a substituted co-polyamino acid |
| US9381247B2 (en) * | 2012-04-16 | 2016-07-05 | Biodel Inc. | Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain |
| US20150314003A2 (en) | 2012-08-09 | 2015-11-05 | Adocia | Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer |
| FR2997857B1 (fr) * | 2012-11-14 | 2020-11-06 | Adocia | Formulation a action rapide d'insuline comprenant un compose anionique substitue |
| CN104902922B (zh) * | 2012-11-13 | 2017-12-12 | 阿道恰公司 | 包含经取代阴离子化合物的速效胰岛素制剂 |
| EP2920200A1 (fr) | 2012-11-13 | 2015-09-23 | Adocia | Composes anioniques substitues constitues d'un squelette forme d'un nombre discret d'unites saccharidiques |
| US9795678B2 (en) | 2014-05-14 | 2017-10-24 | Adocia | Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound |
| FR3020947B1 (fr) | 2014-05-14 | 2018-08-31 | Adocia | Composition aqueuse comprenant au moins une proteine et un agent solubilisant, sa preparation et ses utilisations |
| TW201630622A (zh) | 2014-12-16 | 2016-09-01 | 美國禮來大藥廠 | 速效胰島素組合物 |
| JO3749B1 (ar) | 2015-08-27 | 2021-01-31 | Lilly Co Eli | تركيبات إنسولين سريعة المفعول |
| FR3043557B1 (fr) | 2015-11-16 | 2019-05-31 | Adocia | Composition a action rapide d'insuline comprenant un citrate substitue |
| GB201607918D0 (en) | 2016-05-06 | 2016-06-22 | Arecor Ltd | Novel formulations |
| CN110662551B (zh) | 2017-06-01 | 2023-07-18 | 伊莱利利公司 | 速效胰岛素组合物 |
| US10799564B1 (en) * | 2019-05-06 | 2020-10-13 | Baxter International Inc. | Insulin premix formulation and product, methods of preparing same, and methods of using same |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2847385A (en) | 1954-10-07 | 1958-08-12 | Ohio Commw Eng Co | Detergent-soil suspending composition containing carboxymethyl dextran |
| IT1053718B (it) * | 1973-04-04 | 1981-10-10 | Zambeletti Spa L | Metodo per prolungare l azione di farmaci attraverso la formazione di composti mcromolecolari |
| US4006059A (en) * | 1974-07-29 | 1977-02-01 | Purdue Research Foundation | Hydrophobic noncovalent binding of proteins to support materials |
| AU550068B2 (en) | 1981-03-10 | 1986-02-27 | Novo Nordisk A/S | Zinc insulin stabilized with calcium or magnesium salts |
| WO1985001890A1 (fr) | 1983-10-26 | 1985-05-09 | Kanebo, Ltd. | Agent emulsifiant proteique, son procede de preparation et preparation cosmetique emulsifiee le contenant |
| PH25772A (en) | 1985-08-30 | 1991-10-18 | Novo Industri As | Insulin analogues, process for their preparation |
| IE62879B1 (en) | 1987-02-25 | 1995-03-08 | Novo Nordisk As | Novel insulin derivatives |
| JP3122128B2 (ja) | 1989-12-21 | 2001-01-09 | ノボ ノルディスク アクティーゼルスカブ | ペプチド製剤 |
| CA2035248A1 (en) | 1990-02-06 | 1991-08-07 | Shang-Ren Wu | Vinyl carbamate compounds and detergent compositions containing them |
| AU653026B2 (en) | 1991-06-07 | 1994-09-15 | Teikoku Seiyaku Kabushiki Kaisha | Physiologically active polypeptide-containing pharmaceutical composition |
| NZ260933A (en) | 1993-07-16 | 1996-07-26 | Hercules Inc | Cation-complexed polysaccharides; use in foods and pharmaceuticals |
| JP3414539B2 (ja) | 1994-05-11 | 2003-06-09 | 有限会社ドット | 経鼻吸収用組成物 |
| US5547929A (en) | 1994-09-12 | 1996-08-20 | Eli Lilly And Company | Insulin analog formulations |
| AUPO066096A0 (en) | 1996-06-26 | 1996-07-18 | Peptide Delivery Systems Pty Ltd | Oral delivery of peptides |
| WO1999034821A1 (en) | 1998-01-09 | 1999-07-15 | Novo Nordisk A/S | Stabilised insulin compositions |
| FR2781485B1 (fr) * | 1998-07-21 | 2003-08-08 | Denis Barritault | Polymeres biocompatibles leur procede de preparation et les compositions les contenant |
| US20020141946A1 (en) | 2000-12-29 | 2002-10-03 | Advanced Inhalation Research, Inc. | Particles for inhalation having rapid release properties |
| JP2005504715A (ja) | 2000-12-29 | 2005-02-17 | アドバンスト インハレーション リサーチ，インコーポレイテッド | 持続放出特性を有する吸入用粒子 |
| US7297690B2 (en) | 2003-02-24 | 2007-11-20 | Japan Science And Technology Agency | Fluorescent lanthadine complex |
| BRPI0408105A (pt) * | 2003-03-04 | 2006-03-01 | Thetechnology Dev Company Ltd | sistema de distribuição para droga e terapia celular |
| ATE373444T1 (de) | 2003-04-22 | 2007-10-15 | Biodel Inc | Kissen zur hautreinigung und hautbefeuchtung |
| US7658721B2 (en) | 2004-01-16 | 2010-02-09 | Biodel Inc. | Sublingual drug delivery device |
| US20080090753A1 (en) | 2004-03-12 | 2008-04-17 | Biodel, Inc. | Rapid Acting Injectable Insulin Compositions |
| US20080096800A1 (en) | 2004-03-12 | 2008-04-24 | Biodel, Inc. | Rapid mucosal gel or film insulin compositions |
| US7279457B2 (en) | 2004-03-12 | 2007-10-09 | Biodel, Inc. | Rapid acting drug delivery compositions |
| FR2914305B1 (fr) * | 2007-03-29 | 2009-07-03 | Proteins & Peptides Man | Dextran fonctionnalise par des amino-acides hydrophobes. |
| FR2891149B1 (fr) | 2005-09-26 | 2007-11-30 | Biodex Sarl | Composition pharmaceutique a action cicatrisante comprenant un derive de dextrane soluble et un facteur de croissance derive des plaquettes. |
| US20070244467A1 (en) | 2005-09-28 | 2007-10-18 | Biodel, Inc., State Of Incorporation Delaware | Self-Filling Two Chamber Injectable Device |
| US7713929B2 (en) | 2006-04-12 | 2010-05-11 | Biodel Inc. | Rapid acting and long acting insulin combination formulations |
| WO2007041481A1 (en) | 2005-09-29 | 2007-04-12 | Biodel, Inc. | Rapid acting and prolonged acting insulin preparations |
| US20070191757A1 (en) | 2006-02-16 | 2007-08-16 | Biodel Inc. | Method and Device for Sublingual Drug Delivery Using Iontophoresis |
| CN101460523A (zh) * | 2006-04-07 | 2009-06-17 | 阿道恰公司 | 双官能化多糖 |
| EP2012817A2 (en) | 2006-04-12 | 2009-01-14 | Biodel, Inc. | Rapid acting and long acting insulin combination formulations |
| US20120041079A1 (en) | 2006-09-26 | 2012-02-16 | Adocia | Dextran functionalized by hydrophobic amino acids |
| GB0700523D0 (en) | 2007-01-11 | 2007-02-21 | Insense Ltd | The Stabilisation Of Proteins |
| WO2008124522A2 (en) | 2007-04-04 | 2008-10-16 | Biodel, Inc. | Amylin formulations |
| JP5552046B2 (ja) | 2007-06-13 | 2014-07-16 | ノボ・ノルデイスク・エー／エス | インスリン誘導体を含有する薬学的製剤 |
| BRPI0906553A2 (pt) | 2008-04-14 | 2015-07-07 | Adocia | ''implante aberto constituído por uma composição osteogênica e método de preparação do implante'' |
| WO2010028055A1 (en) | 2008-09-02 | 2010-03-11 | Biodel, Inc. | Insulin with a basal release profile |
| FR2940802A1 (fr) | 2008-10-10 | 2010-07-09 | Adocia | Complexe entre l'insuline humaine et un polymere amphiphile et utilisation de ce complexe pour la preparation d'une formulation d'insuline humaine rapide. |
| FR2936800B1 (fr) | 2008-10-06 | 2010-12-31 | Adocia | Polysaccharide comportant des groupes fonctionnels carboxyles substitues par un derive d'alcool hydrophobe |
| US8759322B2 (en) | 2008-11-05 | 2014-06-24 | National University Corporation Tokyo Medical And Dental University | Hyaluronic acid derivative and pharmaceutical composition thereof |
| FR2948573B1 (fr) | 2009-07-31 | 2011-11-18 | Adocia | Nouvelle forme d'administration de complexes de proteines osteogeniques |
| US9060927B2 (en) | 2009-03-03 | 2015-06-23 | Biodel Inc. | Insulin formulations for rapid uptake |
| FR2943538B1 (fr) | 2009-03-27 | 2011-05-20 | Adocia | Formulation a action rapide d'insuline recombinante humaine |
| US20120094902A1 (en) | 2009-03-27 | 2012-04-19 | Adocia | Fast-acting insulin formulation |
| US9018190B2 (en) | 2009-03-27 | 2015-04-28 | Adocia | Functionalized oligosaccharides |
| KR101775000B1 (ko) | 2009-06-26 | 2017-09-04 | 노보 노르디스크 에이/에스 | 인슐린, 니코틴아미드 및 아미노산을 포함하는 제제 |
| BR112012019580A2 (pt) | 2010-02-09 | 2020-08-18 | Adocia | "polissacarídeos antônicos funcionalizados por pelo menos dois grupos hidrofóbicos carreados por pelo menos um espaçador trivalente |
| US20120295833A1 (en) | 2011-05-10 | 2012-11-22 | Adocia | Polysaccharides having an adjustable degree of functionalization |
-
2009
- 2009-03-27 FR FR0901478A patent/FR2943538B1/fr active Active
-
2010
- 2010-03-26 BR BRPI1006231-9A patent/BRPI1006231A2/pt not_active IP Right Cessation
- 2010-03-29 KR KR1020117025093A patent/KR20110137815A/ko not_active Withdrawn
- 2010-03-29 CA CA2756074A patent/CA2756074A1/fr not_active Abandoned
- 2010-03-29 AU AU2010240664A patent/AU2010240664A1/en not_active Abandoned
- 2010-03-29 CN CN2010800140026A patent/CN102369019A/zh active Pending
- 2010-03-29 US US12/662,036 patent/US8669227B2/en not_active Expired - Fee Related
- 2010-03-29 RU RU2011143313/15A patent/RU2500420C2/ru not_active IP Right Cessation
- 2010-03-29 EP EP10714961.9A patent/EP2411037B1/fr not_active Not-in-force
- 2010-03-29 SG SG2011069309A patent/SG174912A1/en unknown
- 2010-03-29 JP JP2012501407A patent/JP2012521980A/ja not_active Withdrawn
- 2010-03-29 WO PCT/IB2010/000711 patent/WO2010122385A1/fr not_active Ceased
- 2010-03-29 MX MX2011010071A patent/MX2011010071A/es not_active Application Discontinuation
-
2011
- 2011-09-13 IL IL215122A patent/IL215122A0/en unknown
- 2011-09-15 ZA ZA2011/06755A patent/ZA201106755B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2756074A1 (fr) | 2010-10-28 |
| KR20110137815A (ko) | 2011-12-23 |
| IL215122A0 (en) | 2011-12-29 |
| RU2011143313A (ru) | 2013-05-10 |
| CN102369019A (zh) | 2012-03-07 |
| EP2411037A1 (fr) | 2012-02-01 |
| US8669227B2 (en) | 2014-03-11 |
| ZA201106755B (en) | 2014-03-26 |
| FR2943538A1 (fr) | 2010-10-01 |
| EP2411037B1 (fr) | 2017-04-12 |
| MX2011010071A (es) | 2011-10-17 |
| AU2010240664A1 (en) | 2011-10-06 |
| SG174912A1 (en) | 2011-11-28 |
| RU2500420C2 (ru) | 2013-12-10 |
| US20100249020A1 (en) | 2010-09-30 |
| WO2010122385A1 (fr) | 2010-10-28 |
| WO2010122385A8 (fr) | 2010-12-23 |
| FR2943538B1 (fr) | 2011-05-20 |
| JP2012521980A (ja) | 2012-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1006231A2 (pt) | ''complexo composto por ma insulina e um polissacarídeo contendo grupos carboxila funcionais, composição farmacêutica e uso do complexo'' | |
| BR112012012947A2 (pt) | forma cristalina e amorfa de hemitartarato genz 112638 como inibidor de glicosilceramida sintase | |
| MX342563B (es) | Composiciones para el cuidado de la piel. | |
| BR112015013809A2 (pt) | derivados de exendina-4 como agonistas duplos de glp1/gip ou trigonais de glp1/gip/lucagon, seu uso e composição farmacêutica | |
| BR112012012657A2 (pt) | morfolinotiazóis como moduladores alostéricos positivos alfa 7 | |
| BR112012026338A2 (pt) | novos derivados de 3,3-dimetil tetrahidroquinolina | |
| BR112015003592A2 (pt) | derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e seu uso no tratamento de infecções bacterianas | |
| BR122020001787A8 (pt) | Conjugado de anticorpo-agente ativo, seus métodos de preparação, sua composição e seu uso | |
| CA2863681A1 (en) | Topical use of a skin-commensal prebiotic agent and compositions containing the same | |
| BR112012017605A2 (pt) | emulsão acrílica associativa contendo um monómero a base de oxo-álcool, seu método de fabricação, e método para espessamento de uma formulação aquosa usando esta emulsão | |
| BR112014011162A2 (pt) | derivados purínicos para o tratamento de infecções virais | |
| BRPI0905080B8 (pt) | composição de sulfoalquil éter ciclodextrina (sae-cd), processos para preparar uma composição de sulfoalquil éter ciclodextrina (sae-cd), processo para preparar uma composição e produto | |
| BR112013019628A2 (pt) | conjugados de polímero-carboidrato-lipídeo | |
| SG10201901713RA (en) | Extracellular matrix compositions | |
| BR112013031485A2 (pt) | "anticorpos anti-psl de pseudomonas, seus método de produção e uso na prevenção ou no tratamento de infecção por pseudomonas, polinucleotídeo, 5 vetor, composição farmacêutica, bem como métodos in vitro para bloqueio ou prevenção da ligação de p. aeruginosa a células epiteliais e para aumento de morte opsonofagocítica de p. aeruginosa" | |
| BR112012032979B8 (pt) | Composição para limpeza da pele límpida, de baixa irritação, e com ph relativamente baixo e método de limpeza da pele | |
| BR112014032201A2 (pt) | eletrodo de enzima | |
| BR112014015940A8 (pt) | composição de novo fármaco de carboidrato para tratamento de doenças humanas | |
| BR112013011845B8 (pt) | enxaguatório bucal compreendendo aminoácido básico e conservante e uso cosmético do enxaguatório bucal | |
| CL2009000757A1 (es) | Compuestos derivados de 6,8,2´-tris-(isobut-2-en-1-il)-diosmetina; procedimientos para su elaboracion; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades venosas cronicas, sindrome post-trombotico, complicaciones vasculares ligadas a la diabetes, entre otras. | |
| BR112014002958A2 (pt) | "3,4-di-hidro-1h-[1,8]naftiridinonas substituídas com piperidinila antibacterianas, composição farmacêutica compreendendo os referidos compostos, processos para preparação destes e uso". | |
| MX342842B (es) | Composiciones que tienen concentraciones incrementadas de carboximetilcelulosa. | |
| MX2009005679A (es) | Fluoresceina sustancialmente pura. | |
| MX2011010547A (es) | Composiciones farmaceuticas estables de diclofenaco. | |
| BRPI0908569B8 (pt) | estimuladores de secreção de insulina derivados de piridopirazinonas, seu uso, e composição farmacêutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A, 6A, 7A, 8A E 9A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2517 DE 02-04-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |